Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Morphological differentiation of oligodendrocytes requires activation of Fyn tyrosine kinase.
Endogenous retroviruses and multiple sclerosis--new pieces to the puzzle.
Calpain inhibition attenuated morphological and molecular changes in skeletal muscle of experimental allergic encephalomyelitis rats.
Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies.
Estimation of the effect of dalfampridine on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study.
Potassium-Retaining Diuretics: Amiloride
Patient page. Multiple sclerosis and vitamin D.
UPDATE 2-FDA panel supports approval of Sanofi's MS drug Lemtrada
Idebenone delays the onset of cardiac functional alteration without correction of Fe-S enzymes deficit in a mouse model for Friedreich ataxia.
Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg Compared to Daily COPAXONE® 20 mg
Normal outcome of pregnancy with ongoing treatment with natalizumab.
Reduced expression of PGC-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex.
From "Wheelchair Circuit" to "Wheelchair Assessment Instrument for People with Multiple Sclerosis": Reliability and Validity Analysis of a Test to Assess Driving Skills in Manual Wheelchair Users With Multiple Sclerosis.
A genome screen for multiple sclerosis in Italian families.
Investigating Axonal Damage in Multiple Sclerosis by Diffusion Tensor Spectroscopy.
High dose naltrexone for dyskinesias induced by levodopa.
Teva Announces Approval of Three-Times-A-Week COPAXONE® 40 mg/mL in Russia for the Treatment of Relapsing-Remitting Multiple Sclerosis
Astrocytes Underlie Neuroinflammatory Memory Impairment.
Opposite Roles of NMDA Receptors in Relapsing and Primary Progressive Multiple Sclerosis.
Positive year one results from Biogen Idec's Phase 3 advance trial of PLEGRIDY™ (peginterferon beta-1a) presented at AAN meeting
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Assessment of the effect of interferon-beta1a therapy on thyroid and salivary gland functions in patients with multiple sclerosis using quantitative salivary gland scintigraphyz.
The value of specialty pharmaceuticals - a systematic review.
Bullous pemphigoid in a patient with multiple sclerosis being treated with human immunoglobulin.

Pages